Effect of Entacapone on Bodyweight Loss in Obese Population

• Status: Unknown status
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, controlled, double blind clinical trial. The purpose of this study is to investigate the weight loss efficacy of entacapone. In this study, participants are randomly divided into entacapone and placebo groups. The percentage change in body weight, the body mass index, waist circumstance, extent of fatty liver, quantity of visceral fat, serum insulin, serum triglyceride and the adverse effects are compared between the two groups.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kaichun Wu
• Collaborator: National Institute of Biological Sciences, Beijing
• Treatments: Entacapone

Criteria

Inclusion Criteria:

• 1) Obese which is defined as BMI ≥ 28kg/m2 ;

• 2) 18≤ age ≤60 years;

• 3) Permanent resident in Xi'an City, Shaanxi Province, China

Exclusion Criteria:

• 1) Unable to closely follow the diet and exercise regime;

• 2) Bodyweight changes beyond 4kg within 3 month before participating in this study;

• 3) Have a history of myocardial infarction or unstable angina within 6 month before participating in this study;

• 4) With endocrine, neurological, psychiatric or malignant diseases;

• 5) History of thyroid diseases;

• 6) Cardiac, hepatic and renal dysfunction;

• 7) Have a long history of using amcinonide;

• 8) With intestinal malabsorption;

• 9) With history of acute or chronic pancreatitis

• 10) With history of gastrointestinal surgery;

• 11) With history of bariatric surgery;

• 12) Using any other pharmacological drugs for weight loss;

• 13) Addicted to any drugs including alcohol;

• 14) Diabetes;